Security National Bank acquired a new stake in Eli Lilly and Company (NYSE:LLY) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,156 shares of the company’s stock, valued at approximately $216,000.
Other institutional investors and hedge funds also recently modified their holdings of the company. Perennial Advisors LLC bought a new position in Eli Lilly and during the fourth quarter worth about $31,000. Retirement Group LLC bought a new position in Eli Lilly and during the fourth quarter worth about $33,000. DB Wealth Management Group LLC bought a new position in Eli Lilly and during the fourth quarter worth about $34,000. Accel Wealth Management bought a new position in Eli Lilly and during the fourth quarter worth about $37,000. Finally, Archer Investment Corp increased its position in Eli Lilly and by 83.3% during the fourth quarter. Archer Investment Corp now owns 220 shares of the company’s stock worth $37,000 after acquiring an additional 100 shares during the period. 75.59% of the stock is currently owned by institutional investors.
A number of equities analysts recently commented on LLY shares. Truist raised their price target on shares of Eli Lilly and from $200.00 to $215.00 in a research report on Monday, February 1st. Barclays raised their price target on shares of Eli Lilly and from $190.00 to $232.00 and gave the stock an “overweight” rating in a research report on Monday, February 1st. Truist Securities increased their price objective on shares of Eli Lilly and from $215.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, March 22nd. Morgan Stanley increased their price objective on shares of Eli Lilly and from $190.00 to $217.00 and gave the stock an “overweight” rating in a research note on Thursday, February 4th. Finally, Cowen increased their price objective on shares of Eli Lilly and from $195.00 to $235.00 and gave the stock an “outperform” rating in a research note on Friday, February 12th. Four research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $193.88.
In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 13th. The shares were sold at an average price of $185.97, for a total value of $39,053,700.00. Following the completion of the transaction, the insider now owns 110,807,418 shares in the company, valued at approximately $20,606,855,525.46. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In the last quarter, insiders sold 555,284 shares of company stock valued at $106,132,302. 0.09% of the stock is owned by company insiders.
Shares of LLY traded up $1.61 during mid-day trading on Thursday, reaching $183.93. The company had a trading volume of 22,308 shares, compared to its average volume of 4,374,581. The company’s 50 day simple moving average is $195.68 and its 200 day simple moving average is $171.39. Eli Lilly and Company has a 1-year low of $129.21 and a 1-year high of $218.00. The company has a debt-to-equity ratio of 3.27, a quick ratio of 1.06 and a current ratio of 1.36. The company has a market capitalization of $176.39 billion, a price-to-earnings ratio of 29.79, a P/E/G ratio of 1.57 and a beta of 0.37.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Thursday, January 28th. The company reported $2.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.35 by $0.40. The business had revenue of $7.44 billion during the quarter, compared to analyst estimates of $7.27 billion. Eli Lilly and had a net margin of 24.01% and a return on equity of 166.45%. The firm’s quarterly revenue was up 21.7% on a year-over-year basis. During the same quarter last year, the business earned $1.73 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 7.56 earnings per share for the current fiscal year.
About Eli Lilly and
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
Read More: How to read a candlestick chart
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.